No Data
Shuttle Pharma Enters Into Sponsored Research Agreement With the University of California, San Francisco to Advance PSMA Development Program
Express News | Shuttle Pharma Enters Into Sponsored Research Agreement With the University of California, San Francisco to Advance Psma Development Program
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma as UVA Cancer Center Doses Its First Patient
US Manufacturing Index Rises To 43, Highest Since 2020
Shuttle Pharmaceuticals Holdings, Inc. Advances Phase 2 Clinical Trial for Ropidoxuridine in Glioblastoma Treatment
Express News | Shuttle Pharmaceuticals Q3 EPS $(1.59) Down From $(0.91) YoY
